Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
Yikai Wang, Zhenxia Chen, Meibi Dai, et al.
Bioorganic & Medicinal Chemistry Letters (2017) Vol. 27, Iss. 11, pp. 2420-2423
Closed Access | Times Cited: 18

Showing 18 citing articles:

Advances in covalent kinase inhibitors
Ayah Abdeldayem, Yasir S. Raouf, Stefan N. Constantinescu, et al.
Chemical Society Reviews (2020) Vol. 49, Iss. 9, pp. 2617-2687
Closed Access | Times Cited: 256
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
Xiaoyun Lu, Hao Chen, Adam V. Patterson, et al.
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 6, pp. 2905-2915
Closed Access | Times Cited: 74
Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver
Guozhen Cui, Robert C.G. Martin, Hang Jin, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 48
Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma
Zhenpeng Zhong, Liyang Shi, Tiancheng Fu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 10, pp. 7278-7295
Closed Access | Times Cited: 23
2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4
Thomas Knoepfel, Pascal Furet, Robert Mah, et al.
ACS Medicinal Chemistry Letters (2018) Vol. 9, Iss. 3, pp. 215-220
Open Access | Times Cited: 40
Discovery of 1,6-Naphthyridin-2(1H)-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma
Xiaomeng Zhang, Shaobin Wang, Jianfeng Ji, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7595-7618
Closed Access | Times Cited: 20
Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region
Robin A. Fairhurst, Thomas Knoepfel, Catherine Leblanc, et al.
MedChemComm (2017) Vol. 8, Iss. 8, pp. 1604-1613
Open Access | Times Cited: 39
Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
Manman Wei, Peng Xia, Li Xing, et al.
European Journal of Medicinal Chemistry (2018) Vol. 154, pp. 9-28
Closed Access | Times Cited: 34
Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges
Xiaolu Chen, Yajiao Huang, B. Chen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115947-115947
Closed Access | Times Cited: 10
Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4
Xiaojing Lin, Y. Yosaatmadja, Maria Kalyukina, et al.
ACS Medicinal Chemistry Letters (2019) Vol. 10, Iss. 8, pp. 1180-1186
Open Access | Times Cited: 23
Making Way for Suppressing the FGF19/FGFR4 Axis in Cancer
Néstor Prieto‐Domínguez, Austin Y. Shull, Yong Teng
Future Medicinal Chemistry (2018) Vol. 10, Iss. 20, pp. 2457-2469
Closed Access | Times Cited: 21
Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer
Yanan Liu, Canwei Wang, Jifa Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 14
Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer
Xiaolu Chen, Yanan Liu, Liting Zhang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 214, pp. 113219-113219
Closed Access | Times Cited: 12
Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors
Chenghao Pan, Wenwen Nie, Jiao Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113794-113794
Closed Access | Times Cited: 12
Fibroblast growth factor receptor inhibitors: patent review (2015–2019)
Giuseppe Marseglia, Alessio Lodola, Marco Mor, et al.
Expert Opinion on Therapeutic Patents (2019) Vol. 29, Iss. 12, pp. 965-977
Closed Access | Times Cited: 12
The integration of genomics testing and functional proteomics in the era of personalized medicine
Masaru Katoh
Expert Review of Proteomics (2017) Vol. 14, Iss. 12, pp. 1055-1058
Open Access | Times Cited: 6
Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies
Changan Sun, Lei Fang, Xiaobing Zhang, et al.
Bioorganic & Medicinal Chemistry (2019) Vol. 27, Iss. 10, pp. 1932-1941
Closed Access | Times Cited: 5
6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation
Chhabi Lal Chaudhary, Dongchul Lim, Prakash Chaudhary, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 844-856
Open Access | Times Cited: 3
Page 1

Scroll to top